Zohar is the CEO of NGT3 VC. Former CEO & director of Beta-O2 (developed implantable bio-artificial pancreas). Served as CEO of the Technion Technological Incubator. Led the establishment and investment of more than 50 companies, such as Prolor Biotech (sold to OPKO, NYSE: OPK), Mazor (NASDAQ: MZOR), Corindus (NASDAQ: CVRS), ReWalk (NASDAQ: RWLK), and others.
Ron has vast experience in the pharmaceutical & medical device industry, currently serving as a Director in several privately and publicly held companies. On his last position, Ron served as CEO of Teva Israel and V.P. Israel & Africa, Teva Pharmaceutical Industries Ltd. Ron’s core expertise are marketing, sales & distribution, M&A, Business, and Strategic Development. Ron holds a B.Sc. in Industrial Engineering & Management of Ben-Gurion University and MBA of Tel-Aviv University.
Oded served as an executive in several companies, startups and corporates in Israel, Germany and the US, including GE, Roche GmBH, Medingo (sold to Roche), DoD, and Kornit Digital (NASDAQ:KRNT) in various business leadership, marketing, and R&D roles. Oded holds a B.Sc in EE and MBA from the Technion.